首页> Contemporary clinical trials communications> Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).

导出 LinkOut

翻译打印收藏纠错

第一作者： Anna,Ozaki

第一单位： Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.

作者： Anna,Ozaki ^[1] ; Masato,Yoneda ^[1] ; Takaomi,Kessoku ^[2] ; Michihiro,Iwaki ^[1] ; Takashi,Kobayashi ^[1] ; Yasushi,Honda ^[2] ; Yuji,Ogawa ^[1] ; Kento,Imajo ^[1] ; Eiji,Sakai ^[1] ; Masataka,Taguri ^[3] ; Takeharu,Yamanaka ^[4] ; Tomoyuki,Iwasaki ^[5] ; Takeo,Kurihashi ^[6] ; Satoru,Saito ^[1] ; Atsushi,Nakajima ^[1]

作者单位： Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. ^[1] Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.;Department of Palliative Care Center Yokohama City University Hospital, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. ^[2] Department of Data Science, Yokohama City University School of Data Science, 2-22 Seto, Kanazawa-ku, Yokohama, 236-0027, Japan. ^[3] Department of Biostatistics, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. ^[4] Iwasaki Internal Medicine Clinic, 1-1-5 Furu-ruyokohama1F, Kamihoshikawa, Hodogaya-ku, Yokohama, Kanagawa, 240-0042, Japan. ^[5] Department of Internal Medicine, Yokohama Clinic, Kanagawa Dental University, 3-31-6 Tsuruya-cho, Kanagawa, Yokohama, Kanagawa, 221-0835, Japan. ^[6]

关键词 AE, adverse event ALT, alanine aminotransferase CRF, case report form DM, diabetes mellitus Diabetes mellitus FAS, full analysis set HbA1c, glycated hemoglobin Hepatic steatosis MRI-Based proton density fat fraction MRI-PDFF, magnetic resonance imaging-based proton density fat fraction NAFLD, non-alcoholic fatty liver disease NASH, non-alcoholic steatohepatitis Non-alcoholic fatty liver disease PPS, per protocol set Pioglitazone SPIRIT, the Standard Protocol Items: Recommendations for Interventional Trials Tofogliflozin jRCTs, the Japan Registry of Clinical Trials

DOI 10.1016/j.conctc.2019.100516

PMID 31956725

发布时间 2024-07-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Contemporary clinical trials communications

2020年17卷

100516页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Contemporary clinical trials communications

2020年17卷

100516页

检索历史清除

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).

Contemporary clinical trials communications

相似文献

同项目论文

Contemporary clinical trials communications

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).

Contemporary clinical trials communications

相似文献

同项目论文

Contemporary clinical trials communications

相关期刊

检索历史清除